Uncovering Medicare Formulary Restrictions for Diabetes & Obesity Patients to Identify Treatment Gaps & Work Towards Increased Coverage
Time: 12:00 pm
day: Conference Day One
Details:
- Discussing Benefits of GLP-1s related to the decrease in cardiovascular events, heart failure hospitalizations and kidney disease progression
- Outlining the American Diabetes Associations updated guidelines to increase the use of GLP-1s as potential first -line options for patients with cardio-renal conditions
- Navigating formulary restrictions such as step therapy and prior authorizations to increase patient access to GLP-1s
